BridgeMD
Tests treatment safety and results for Type II Diabetes Mellitus
Official title Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study
ClinicalTrials.gov ID: NCT05164263
What this study is testing
What is Empagliflozin?
Empagliflozin is an investigational medicine, being studied as a potential treatment for type ii diabetes mellitus.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population. Study design Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65. Healthy volunteers may be eligible.
You may be able to join if
- Patient with T2DM between 18 to 65 years with HbA1C 7% - 10%, who can give informed consent. Patient uncontrolled on oral antidiabetics and lifestyle...
You likely can't join if
- Type 1 diabetes, History of recurrent urinary tract infection (UTI), fungal infection, renal and/or hepatic dysfunctions, where RFT and Urine R/E is...
The study team makes the final eligibility decision.
Where it's taking place
- Kabul, Afghanistan, Afghanistan
- Nairobi, Kenya, Kenya
- Lagos, Nigeria, Nigeria
- Islamabad, Pakistan
- Colombo, Colombo, Sri Lanka
- Kandy, Kandy, Sri Lanka
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kabul, Afghanistan, Afghanistan; Nairobi, Kenya, Kenya; Lagos, Nigeria, Nigeria; Islamabad, Pakistan; Colombo, Colombo, Sri Lanka; Kandy, Kandy, Sri Lanka. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.